FDA Approves Apixaban the Generic Alternative to Eliquis

If you're in search of a cost-effective alternative to Eliquis, a popular blood thinner prescription medication, we have great news for you. On December 23, 2019, the U.S. Food and Drug Administration (FDA) granted approval for the first generics of Eliquis, known as apixaban tablets.

Understanding Eliquis (Apixaban):

Eliquis, also known by its generic name, apixaban, is an effective blood thinner that operates by inhibiting a clotting enzyme called Factor Xa. Initially introduced by Bristol-Myers Squibb and marketed by Pfizer in 2012, this medication garnered considerable attention from cardiologists due to its potential in managing specific blood clotting risks. Eliquis became the third novel oral anticoagulant to receive FDA approval, following Pradaxa and Xarelto. It's important to note that Genericmedicine.com offers both Eliquis and its generic alternative, Apixaban, for your convenience.

Why Choose Apixaban as a Generic Alternative to Eliquis:

Direct oral anticoagulants like Apixaban have largely supplanted older treatments such as Coumadin (warfarin), which require more frequent monitoring and carry numerous potential drug interactions. Another newer alternative to Eliquis is Xarelto. One of the key advantages of Apixaban is that patients using it do not need repeated blood testing, making it a more convenient and accessible option for many individuals.

Availability of Generic Eliquis (Apixaban):

The FDA granted generic approvals for Apixaban (Eliquis) in 2019 to two pharmaceutical companies: Micro Labs Limited and Mylan Pharmaceuticals Inc. However, legal battles between Bristol-Myers Squibb, Pfizer, and the generic manufacturers resulted in a U.S. Court of Appeals ruling in September 2021, temporarily delaying the introduction of generic Apixaban to the market. As per the manufacturers of Eliquis, it is unlikely that generics will become available before April 1, 2028, subject to ongoing legal proceedings.